Windward Bio is a clinical-stage drug development company focused on creating treatments for severe respiratory conditions, including asthma and COPD, using long-acting monoclonal antibodies and bispecifics.

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders.

Aviceda Therapeutics is a biotech company developing next-generation immunomodulators for ophthalmic conditions using its proprietary HALOS™ nanotechnology platform.

SiteOne Therapeutics is a biopharmaceutical company developing selective, small molecule ion channel modulators for treating sensory hyperexcitability disorders like pain and chronic cough.

Angitia Biopharmaceuticals is a clinical-stage biotechnology company developing novel treatments for serious musculoskeletal diseases.

Adcendo is a biotech company focused on developing antibody-drug conjugates for treating cancers with high unmet needs.

Avenzo Therapeutics is a biotechnology company developing oncology therapies, including a CDK2 inhibitor for advanced solid tumors and HR+/HER2-negative metastatic breast cancer.

Alentis Therapeutics is a biotech company developing antibody-drug conjugates for treating Claudin-1 positive tumors and organ fibrosis.

Leal Therapeutics is a biotechnology company developing treatments for central nervous system disorders, focusing on amyotrophic lateral sclerosis (ALS) and schizophrenia.

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Candid Therapeutics, Inc. is a biotechnology company developing transformative therapies for autoimmune diseases.

Odyssey Therapeutics is a biotech firm specializing in developing precision immunomodulators and oncology medicines, with plans to advance multiple therapeutic programs into clinical studies.

Koya Medical develops innovative treatments for lymphedema and other venous diseases, aiming to provide personalized care for patients suffering from these debilitating conditions.

Forward Therapeutics is a company focused on advancing the development of next-generation small molecule immune therapies.

Terremoto Biosciences is a biotechnology company that has raised $175 million in a Series B financing round to advance its platform and support the development of multiple in-house programs targeting diseases of high unmet medical need.

Triveni Bio is a biotech company developing novel antibody treatments for immunological and inflammatory disorders.

Rampart Bioscience is a biotechnology company developing next-generation biologics using their proprietary DNA-based medicines platform, HALO, with a focus on treating hypophosphatasia.

MinervaX is a Danish biotechnology company that has raised EUR 54 million to advance the development of its maternal vaccine against Group B Streptococcus (GBS), a leading cause of life-threatening infections in newborns.

Evozyne is a biotech company that uses generative AI to discover new drugs and develop gene editors and enzymes that modulate immune response, with a focus on addressing therapeutic challenges and sustainability issues.

Adela is a healthcare technology company that specializes in blood testing for early cancer detection and minimal residual disease monitoring using a genome-wide methylome enrichment platform.

ReCode Therapeutics is a genetic medicines company that uses precision delivery to develop mRNA and gene correction therapeutics, with a focus on treatments for primary ciliary dyskinesia, cystic fibrosis, and other genetic diseases.

Corteria Pharmaceuticals is a biopharmaceutical company that develops first-in-class therapies for unaddressed heart failure subpopulations, with a focus on multi-organ benefits targeting the kidneys, heart, and vessels.

Star Therapeutics is a biotechnology company that develops first-in-class antibody therapies, primarily for hematology and immunology, and also generates additional biotech companies focused on discovering and advancing novel antibody therapies.

Epigenic Therapeutics is a biotechnology company that develops gene editing therapies for various diseases using its proprietary technology platform, EPIREG, which optimizes CRISPR-Cas components for gene regulation without altering DNA sequences and employs a proprietary lipid nanoparticle medicine delivery system.

FORE Biotherapeutics is a precision oncology company that focuses on the clinical development of plixorafenib, a novel small-molecule inhibitor for treating BRAF-altered tumors.